Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.30 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054605 | 1.00 | DHODH (0.33) | DHODHKDRKITFLT1BRD4 | |
| SCHEMBL3060578 | 0.91 | KDR (0.35) | KDRKITFLT1BRD4 | |
| SCHEMBL3062086 | 0.91 | ACHE (0.36) | KDRKITFLT1BRD4 | |
| SCHEMBL3049565 | 0.88 | SPR (0.32) | KDRKITFLT1 | |
| SCHEMBL3049186 | 0.83 | DHODH (0.37) | DHODHKDRKITFLT1BRD4 | |
| SCHEMBL3049179 | 0.83 | DHODH (0.37) | DHODHKDRKITFLT1BRD4 | |
| SCHEMBL3054604 | 0.83 | DHODH (0.37) | DHODHKDRKITFLT1BRD4 | |
| SCHEMBL2778363 | 0.81 | KDR (0.36) | DHODHKDRKITFLT1BRD4 | |
| SCHEMBL3059023 | 0.81 | KDR (0.36) | DHODHKDRKITFLT1BRD4 | |
| SCHEMBL2778366 | 0.81 | KDR (0.36) | DHODHKDRKITFLT1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | TNNI3, TNNT2, ALDH1A2 | DHODH 544/4885KDR 97/4885KIT 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.